Press - Allegro Ophthalmics Accelerated Innovation. Needed Intervention.

Allegro Press Releases

Allegro Ophthalmics Announces Positive Topline Results from DEL MAR Phase 2b Stage 2 Trial Evaluating Luminate^® in Patients with Diabetic Macular Edema

August 09, 2017

Allegro Ophthalmics Secures $10.7 Million in Private Financing

July 24, 2017

Allegro Ophthalmics Names Melvin Sarayba, MD, Vice President Of Clinical Affairs

March 07, 2017

Allegro Ophthalmics Completes Enrollment in DEL MAR Phase 2b, Stage 2 Clinical Trial of Luminate^® for the Treatment of Diabetic Macular Edema

December 15, 2016

William J. Link, PhD, Joins Allegro Ophthalmics’ Board of Directors

November 21, 2016

Allegro Ophthalmics Announces Positive Topline Results from DEL MAR Phase 2b Trial Evaluating Luminate^® in Patients with Diabetic Macular Edema

October 13, 2016

Allegro Ophthalmics Announces Last Patient Enrolled in PACIFIC Phase 2b Clinical Trial of Luminate^® for Non-Proliferative Diabetic Retinopathy

October 03, 2016

Ron Kurtz, MD, and Mark Livingston Join Allegro Ophthalmics’ Board of Directors

August 01, 2016

Allegro Ophthalmics Announces Two Executive Promotions

March 15, 2016

Allegro Ophthalmics Announces Last Patient Enrolled in Del Mar Phase 2b Clinical Trial of Luminate^® for the Treatment of Diabetic Macular Edema

January 05, 2016

Vision & Mission

Bringing Our Vision to Life with Luminate^®
Diabetes is increasing in the general population,¹ and Allegro Ophthalmics foresaw the need to create a treatment to help DME patients. That’s where Luminate^® comes in…

Technology

Learn how Luminate^® uniquely works to stop and even reverse the effects of DME and wet AMD.

Media Inquiries

For media inquiries, please contact: mgray@allegroeye.com